» Articles » PMID: 35511736

CD44-fibrinogen Binding Promotes Bleeding in Acute Promyelocytic Leukemia by in Situ Fibrin(ogen) Deposition

Overview
Journal Blood Adv
Specialty Hematology
Date 2022 May 5
PMID 35511736
Authors
Affiliations
Soon will be listed here.
Abstract

Early hemorrhagic death is still the main obstacle for the successful treatment of acute promyelocytic leukemia (APL). However, the mechanisms underlying hemostatic perturbations in APL have not been fully elucidated. Here, we report that CD44 on the membrane of APL blasts and NB4 cells ligated bound fibrinogen, resulting in in situ deposition of fibrin and abnormal fibrin distribution. Clots formed by leukemic cells in response to CD44 and fibrinogen interaction exhibited low permeability and resistance to fibrinolysis. Using flow cytometry and confocal microscopy, we found that CD44 was also involved in platelet and leukemic cell adhesion. CD44 bound activated platelets but not resting platelets through interaction with P-selectin. APL cell-coated fibrinogen-activated platelets directly induce enhanced procoagulant activity of platelets. In vivo studies revealed that CD44 knockdown shortened bleeding time, increased the level of fibrinogen, and elevated the number of platelets by approximately twofold in an APL mouse model. Moreover, CD44 expression on leukemic cells in an APL mouse model was not only associated with bleeding complications but was also related to the wound-healing process and the survival time of APL mice. Collectively, our results suggest that CD44 may be a potential intervention target for preventing bleeding complications in APL.

Citing Articles

Fibrinogen and tumors.

Wu X, Yu X, Chen C, Chen C, Wang Y, Su D Front Oncol. 2024; 14:1393599.

PMID: 38779081 PMC: 11109443. DOI: 10.3389/fonc.2024.1393599.


Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia.

Hisada Y, Kawano T, Archibald S, Welch J, Reeves B, Mackman N Blood Adv. 2023; 7(18):5458-5469.

PMID: 37450381 PMC: 10515313. DOI: 10.1182/bloodadvances.2023010466.


The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management.

Hermsen J, Hambley B Cancers (Basel). 2023; 15(13).

PMID: 37444587 PMC: 10340352. DOI: 10.3390/cancers15133477.


Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia: An Experience From a Resource-Constraint Country.

Thakur W, Anwar N, Fatima N, Jamal A, Rizvi Q, Borhany M Cureus. 2022; 14(6):e26026.

PMID: 35865439 PMC: 9293264. DOI: 10.7759/cureus.26026.

References
1.
Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y . CD44 in cancer. Crit Rev Clin Lab Sci. 2002; 39(6):527-79. DOI: 10.1080/10408360290795574. View

2.
Cajamarca S, Norris E, van der Weerd L, Strickland S, Ahn H . Cerebral amyloid angiopathy-linked β-amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen. Proc Natl Acad Sci U S A. 2020; 117(25):14482-14492. PMC: 7322009. DOI: 10.1073/pnas.1921327117. View

3.
Meier-Abt F, Lu J, Cannizzaro E, Pohly M, Kummer S, Pfammatter S . The protein landscape of chronic lymphocytic leukemia. Blood. 2021; 138(24):2514-2525. DOI: 10.1182/blood.2020009741. View

4.
Kashyap T, Pramanik K, Nath N, Mishra P, Singh A, Nagini S . Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer. Oral Oncol. 2018; 86:234-243. DOI: 10.1016/j.oraloncology.2018.09.028. View

5.
Wang H, Wu J, Williams G, Fan Q, Niu S, Wu J . Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J Nanobiotechnology. 2019; 17(1):60. PMC: 6513513. DOI: 10.1186/s12951-019-0494-y. View